Compare PL & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PL | QGEN |
|---|---|---|
| Founded | 2010 | 1986 |
| Country | United States | Netherlands |
| Employees | 970 | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.2B |
| IPO Year | N/A | 1998 |
| Metric | PL | QGEN |
|---|---|---|
| Price | $38.42 | $41.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $26.24 | ★ $50.26 |
| AVG Volume (30 Days) | ★ 16.4M | 1.4M |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.88% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.85 | $8.18 |
| Revenue Next Year | $29.44 | $5.71 |
| P/E Ratio | ★ N/A | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.92 | $38.80 |
| 52 Week High | $40.13 | $57.82 |
| Indicator | PL | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 45.53 |
| Support Level | $24.97 | $38.80 |
| Resistance Level | N/A | $48.53 |
| Average True Range (ATR) | 3.35 | 0.81 |
| MACD | 0.28 | 0.39 |
| Stochastic Oscillator | 86.60 | 64.68 |
Planet Labs PBC is an Earth-imaging company. It uses space to help life on Earth by imaging the world every day and making change visible, accessible, and actionable. Its platform includes imagery, insights, and machine learning that empower companies, governments, and communities around the world to make timely decisions about the evolving world. Its solutions are Broad Area Management. Its products are Planet Monitoring, Planet Tasking, Planet Analytic Feeds, Planetary Variables, Planet Basemaps, Planet Insights, and Platform Pricing. The group provides solutions to the Agriculture Science Program, Energy & Infrastructure, Forestry & Land Use, Mapping, Sustainability, Maritime, Civil Government, U.S. State and Local, Europe, Planet Federal, Defense & Intelligence, and Armed Services.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).